Full Description
Monitoring is a major component of management of chronic diseases such as diabetes, cardiovascular disease, arthritis and depression. Yet poor monitoring means healthcare costs are rising. This book discusses how monitoring principles adopted in other spheres such as clinical pharmacology and evidence-based medicine can be applied to chronic disease in the global setting. With contributions from leading experts in evidence-based medicine, it is a ground-breaking text for all involved in delivery of better and more effective management of chronic illnesses.
Contents
Contributors. Part 1 The Theory of Monitoring. INTRODUCTORY MATERIAL. 1 An introduction to monitoring therapeutic interventions in clinical practice (Paul P. Glasziou, University of Oxford; Jeffrey K. Aronson, University of Oxford). 2 A framework for developing and evaluating a monitoring strategy (David Mant, University of Oxford). THE MEASUREMENT. 3 Developing monitoring tools: integrating the pathophysiology of disease and the mechanisms of action of therapeutic interventions (Jeffrey K. Aronson, University of Oxford; Susan Michie, University College London). 4 Biomarkers and surrogate endpoints in monitoring therapeutic interventions (Jeffrey K. Aronson, University of Oxford). 5 Choosing the best monitoring tests (Les Irwig, University of Sydney; Paul P. Glasziou, University of Oxford). THE CONTROL PHASES. 6 Monitoring the initial response to treatment (Katy Bell, University of Sydney; Jonathan Craig, University of Sydney; Les Irwig, University of Sydney). 7 Control charts and control limits in long-term monitoring (Petra Macaskill, University of Sydney). 8 Developing a monitoring schedule: frequency of measurement (Andrew J. Farmer, University of Oxford). 9 How should we adjust treatment? (Paul P. Glasziou, University of Oxford). THE (Susan Michie, University College London; Kirsten McCaffery, University of Sydney); Carl Heneghan, University of Oxford). 11 Monitoring from the patient's perspective: the social and psychological implications (Kirsten McCaffery, University of Sydney; Susan Michie, University College London). costs of monitoring (Patrick M.M. Bossuyt, University of Amsterdam). 13 Good practice in delivering laboratory monitoring (W. Stuart A. Smellie, Bishop Auckland Hospital, County Durham). 14 Point-of-care testing in monitoring (Christopher P. Price, University of Oxford). 15 Monitoring for the adverse effects of drugs (Jamie J. Coleman, Queen Elizabeth Hospital, Birmingham; Robin E. Ferner, City Hospital, Birmingham; Jeffrey K. Aronson, University of Oxford). Part 2 The Practice of Monitoring. 16 Monitoring diabetes mellitus across the lifetime of illness (Andrew J. Farmer, University of Oxford). 17 Oral anticoagulation therapy (OAT) (Carl Heneghan, University of Oxford; Rafael Perera, University of Oxford). 18 Monitoring cholesterol-modifying interventions (Paul P. Glasziou, University of Oxford; Les Irwig, University of Sydney; Stephane Heritier, (University of Sydney). 19 Monitoring levothyroxine replacement in primary hypothyroidism (Andrea Rita Horvath, University of Szeged). 20 Monitoring in renal transplantation (Nicholas B. Cross, University of Sydney; Jonathan Craig, University of Sydney). 21 Monitoring in pre-eclampsia (Pisake Lumbiganon, Khon Kaen University; Malinee Laopaiboon, Khon Kaen University). 22 Monitoring in intensive care (Jan M. Binnekade, University of Amsterdam; Patrick M.M. Bossuyt, University of Amsterdam). 23 Monitoring intraocular pressure in glaucoma (Les Irwig, University of Sydney; Paul R. Healey, University of Sydney; Jefferson D'Assun o, University of Sydney; Petra Macaskill, University of Sydney). 24 Monitoring in osteoarthritis (George Peat, Keele University; Mark Porcheret, Keele University; John Bedson, Keele University; Alison M. Ward, University of Oxford). Index.
